Ovarian cancer test, one of two products being developed, has a pending 510(k).
Vermillion and Quest Diagnostics will extend their diagnostic development alliance until October 2009. This enables the companies to continue work on the development and commercialization of two tests, OVA1™ and Vasclir™.
Vermillion reports that it began its partnership with Quest in 2005 to develop and commercialize diagnostic tests. The OVA1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Vermillion has a pending a 510(k) application before the FDA. Vasclir is a blood test being designed to identify an individual’s risk of developing peripheral artery disease.
